Trial Profile
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 06 Jun 2023 According to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology, Cohort B did not proceed to dose expansion due to emerging therapies in second-line metastatic pancreatic ductal adenocarcinoma patients.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 Sep 2022 Status changed from active, no longer recruiting to completed.